In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share ...
We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Obesity-drug maker Metsera Inc.’s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their stock-market debuts ...
BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...
The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.
In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share, and the ...
In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback